Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement